Tempus, a health IT company advancing precision medicine, received $110 million in as Series E financing round, increasing its total funding to $320 million.
Tempus' platform builds comprehensive molecular and clinical data sets, leveraging machine learning, sequencing and artificial intelligence-assisted image recognition to offer analysis of and insights into the data.
The company will use the funds to grow operations and expand into new therapeutic areas and geographies.
Additionally, Tempus has collaboration agreements with CancerLinQ, a nonprofit subsidiary of the American Society of Clinical Oncology as well as academic medical centers and National Cancer Institute-designated cancer centers, hospital networks and physicians.